Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EMP-01 · 1 trial · 1 indication
Assess the safety and tolerability of EMP-01 compared with placebo (PBO) in participants with SAD.
Assess the safety of EMP-01 compared with placebo (PBO) in participants with SAD.
Assess the safety of EMP-01 compared with placebo (PBO) in participants with SAD.
| Arm | Type | Description |
|---|---|---|
| EMP-01 | EXPERIMENTAL | - |
| EMP-01 Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| EMP-01 | DRUG | EMP-01 capsules |
| EMP-01 Placebo | DRUG | EMP-01 placebo capsules |
Inclusion Criteria: Eligibility will be assessed at Screening and will be reconfirmed on Day -1 (Baseline) based on available information, before randomization on the following day (Day 1). Participants must meet all of the following criteria to be enrolled in this study: Age 1. Participants mus...
EMP-01 is an investigational small molecule being developed for the treatment of Social Anxiety Disorder. It is currently in Phase 2 clinical development. A completed Phase 2 trial evaluated its exploratory safety and efficacy in patients with this condition.
EMP-01 is a small molecule being studied for Social Anxiety Disorder. Its specific molecular target has not been disclosed in the available information.
EMP-01 is being developed by AtaiBeckley Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol ATAI.
EMP-01 is in Phase 2 clinical development for Social Anxiety Disorder. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
EMP-01 has one completed Phase 2 clinical trial, identified as NCT06693609, titled 'Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder.' This randomized, double-blind, placebo-controlled trial enrolled 70 participants in the United Kingdom.